Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXNASDAQ:EXASNYSE:LHNASDAQ:MYGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$165.49-1.1%$165.70$125.42▼$178.87$18.37B0.92877,842 shs769,212 shsEXASExact Sciences$45.67-3.0%$50.15$40.62▼$79.62$8.48B1.252.61 million shs1.52 million shsLHLaboratory Co. of America$233.55-1.2%$245.19$191.97▼$258.59$19.55B1.12597,948 shs637,701 shsMYGNMyriad Genetics$9.73-2.5%$11.97$9.36▼$29.30$888.44M1.79852,212 shs583,015 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics-1.11%-3.91%-4.03%+7.87%+28.04%EXASExact Sciences-3.02%+1.67%-7.29%-21.41%-28.37%LHLaboratory Co. of America-1.14%-2.54%-6.53%+1.77%+9.26%MYGNMyriad Genetics-2.51%-1.72%-31.44%-29.18%-55.73%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.9495 of 5 stars2.35.04.24.73.22.52.5EXASExact Sciences4.4063 of 5 stars4.51.00.04.73.01.70.6LHLaboratory Co. of America4.7309 of 5 stars3.43.02.54.23.02.51.3MYGNMyriad Genetics4.2166 of 5 stars4.13.00.04.12.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.67Moderate Buy$178.387.79% UpsideEXASExact Sciences 2.90Moderate Buy$70.8355.10% UpsideLHLaboratory Co. of America 2.86Moderate Buy$269.9215.57% UpsideMYGNMyriad Genetics 2.20Hold$21.89125.00% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, LH, MYGN, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025DGXQuest DiagnosticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$190.00 ➝ $191.003/13/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$52.003/12/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$11.50 ➝ $12.503/4/2025DGXQuest DiagnosticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$185.00 ➝ $185.003/4/2025LHLaboratory Co. of AmericaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$250.00 ➝ $300.003/4/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $11.503/3/2025MYGNMyriad GeneticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$13.00 ➝ $11.002/26/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.002/25/2025MYGNMyriad GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.00 ➝ $19.002/25/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.002/24/2025EXASExact SciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$70.00 ➝ $73.00(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$9.87B1.86$12.91 per share12.82$61.04 per share2.71EXASExact Sciences$2.76B3.07$5.20 per share8.79$12.93 per share3.53LHLaboratory Co. of America$13.01B1.50$21.06 per share11.09$96.27 per share2.43MYGNMyriad Genetics$837.60M1.06N/AN/A$9.53 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.6921.5215.782.168.80%15.07%6.72%4/22/2025 (Estimated)EXASExact Sciences-$204.15M-$5.57N/A91.34N/A-37.29%-5.29%-2.45%5/6/2025 (Estimated)LHLaboratory Co. of America$746M$8.8226.4813.321.715.73%15.29%7.01%4/24/2025 (Estimated)MYGNMyriad Genetics-$263.30M-$1.41N/AN/AN/A-14.09%-4.51%-3.07%5/6/2025 (Estimated)Latest EXAS, LH, MYGN, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/ADGXQuest Diagnostics$2.18N/AN/AN/A$2.63 billionN/A2/25/2025Q4 2024MYGNMyriad Genetics$0.03-$0.09-$0.12-$0.47$210.35 million$210.60 million2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 million2/6/2025Q4 2024LHLaboratory Co. of America$3.40$3.45+$0.05$1.70$3.31 billionN/A1/30/2025Q4 2024DGXQuest Diagnostics$2.19$2.23+$0.04$1.95$2.58 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.93%+6.94%41.61%14 YearsEXASExact SciencesN/AN/AN/AN/AN/ALHLaboratory Co. of America$2.881.23%N/A32.65%N/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ALatest EXAS, LH, MYGN, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/30/2025DGXQuest Diagnosticsquarterly$0.802.06%4/7/20254/7/20254/21/20251/8/2025LHLaboratory Co. of Americaquarterly$0.721.23%2/27/20252/27/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.821.101.02EXASExact Sciences0.972.151.93LHLaboratory Co. of America0.671.441.30MYGNMyriad Genetics0.051.901.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%LHLaboratory Co. of America95.94%MYGNMyriad Genetics99.02%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.79%EXASExact Sciences1.36%LHLaboratory Co. of America0.85%MYGNMyriad Genetics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics48,000110.98 million110.73 millionOptionableEXASExact Sciences6,400185.76 million182.56 millionOptionableLHLaboratory Co. of America75,50083.70 million82.93 millionOptionableMYGNMyriad Genetics2,70091.31 million89.12 millionOptionableEXAS, LH, MYGN, and DGX HeadlinesRecent News About These CompaniesSei Investments Co. Acquires 174,770 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)March 25 at 4:40 AM | marketbeat.comNatixis Advisors LLC Sells 110,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)March 24 at 3:42 AM | marketbeat.comCharles Schwab Investment Management Inc. Acquires 42,233 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)March 21, 2025 | marketbeat.com1 Small-Cap Stock on Our Watchlist and 2 to AvoidMarch 20, 2025 | uk.finance.yahoo.comAmundi Grows Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)March 20, 2025 | marketbeat.comMyriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?March 17, 2025 | msn.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)March 16, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Shares Gap Up - Should You Buy?March 13, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Raised to Overweight at Piper SandlerMarch 13, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Downgraded by StockNews.com to "Hold"March 13, 2025 | marketbeat.comMyriad Genetics upgraded to Overweight from Neutral at Piper SandlerMarch 12, 2025 | markets.businessinsider.comPiper Sandler Upgrades Myriad Genetics (MYGN)March 12, 2025 | msn.comWhy Are Myriad Genetics (MYGN) Shares Soaring TodayMarch 12, 2025 | msn.comMyriad Genetics upgraded at Piper Sandler on balanced risk reward setupMarch 12, 2025 | msn.comAnalyst Sees Bottom For Myriad Genetics Stock, Issues UpgradeMarch 12, 2025 | benzinga.comMedical Equipment Stock Jumps on UpgradeMarch 12, 2025 | schaeffersresearch.comBuy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid ChallengesMarch 12, 2025 | tipranks.comMyriad Genetics price target lowered to $16 from $21 at Morgan StanleyMarch 11, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Hits New 1-Year Low - Here's What HappenedMarch 11, 2025 | marketbeat.comEssex Investment Management Co. LLC Sells 119,132 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)March 10, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Updates FY 2025 Earnings GuidanceMarch 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyTariffs Won’t Stop These 3 Stocks From RisingBy Chris Markoch | March 5, 2025View Tariffs Won’t Stop These 3 Stocks From Rising3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsBy Leo Miller | March 19, 2025View 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow MarginsEXAS, LH, MYGN, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$165.49 -1.84 (-1.10%) As of 03/25/2025 03:58 PM EasternQuest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXAS$45.67 -1.42 (-3.02%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$45.83 +0.16 (+0.36%) As of 03/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Laboratory Co. of America NYSE:LH$233.55 -2.89 (-1.22%) As of 03/25/2025 03:58 PM EasternLabcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Myriad Genetics NASDAQ:MYGN$9.73 -0.25 (-2.51%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$9.74 +0.00 (+0.05%) As of 03/25/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
